Status:
RECRUITING
Safety and Efficacy of Oral NXC-736 in Adult Participants with Moderate and Severe Alopecia Areata
Lead Sponsor:
NEXTGEN Bioscience
Conditions:
Alopecia Areata
Eligibility:
All Genders
19-65 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of NXC-736 monotherapy in participants with severe alopecia areata (AA).
Eligibility Criteria
Inclusion
- Men or women between ≥19 and ≤65 years of age at the time of informed consent
- Moderate and severe alopecia areata as assessed by a SALT score of 25% ≤ SALT \< 95% at Screening and Day 1/Baseline
- Current episode of hair loss for ≥6 months but \<8 years
- Stable disease condition (no significant growth of hair) in the last 6 months as assessed by the Investigator
- Willing to keep the same hair style and color (eg, hair products, process, and timing for hair appointments) for the duration of the study
Exclusion
- Participants with the following medical history confirmed during screening:
- ohter Types of alopecia other than alopecia areata (such as cicatricial/scarring alopecia \[including central centrifugal cicatricial alopecia\], traction alopecia, androgenic alopecia, telogen effluvium, etc.)
- Active scalp inflammation, scalp infection, scalp psoriasis, or any other scalp condition that may interfere with the SALT assessment
- Previous use of Janus kinase (JAK) inhibitor (oral or topical), including participation in clinical studies of JAK inhibitors
Key Trial Info
Start Date :
September 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2025
Estimated Enrollment :
96 Patients enrolled
Trial Details
Trial ID
NCT06104839
Start Date
September 1 2024
End Date
June 30 2025
Last Update
December 17 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital.
Seoul, South Korea, 03080
2
Kyung Hee University Hospital at Gangdong
Seoul, South Korea, 05278